Meta Platforms is the IBD Stock of the Day for Monday. Shares of the Facebook parent company have formed a flat base pattern after bouncing back last week from a slight earnings letdown. Please watch ...

The biomarker assay can be used potentially to enrich clinical trials and monitor patients' disease activity and treatment response.

A randomized controlled trial finds no clear benefit of adding bezlotoxumab to FMT in patients with IBD and recurrent C difficile infection.

Developing a vaccination program for infectious bursal disease virus (IBDV) challenges should consider the severity and ...

Aeglea Biotherapeutics Inc. ( (SYRE) ) has released its Q3 earnings. Here is a breakdown of the information Aeglea Biotherapeutics Inc.

Google stock has gained 28% in 2024 but shares have ping-ponged since July amid fierce AI competition and antitrust worries.

Alcohol can worsen Crohn’s disease symptoms, but the impact varies from person to person. It may depend on what and how much ...

Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients involves trial and error during the treatment process.

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients ...

Access to health care among patients with IBD includes barriers like financial struggles and challenges in access to treatment.